Screening of infants and mortality due to neuroblastoma

New England Journal of Medicine

Volumn 346, Issue 14, 2002, Pages 1041-1046

  Woods, William G ^a   Gao, Ru Nie ^b   Shuster, Jonathan J ^c   Robison, Leslie L ^d   Bernstein, Mark ^e   Weitzman, Sheila ^f   Bunin, Greta ^g   Levy, Isra ^h   Brossard, Josee ⁱ   Dougherty, Geoffrey ^j   Tuchman, Mendel ^k   Lemieux, Bernard ⁱ  

^a EMORY UNIVERSITY   (United States)

^b STATISTICS CANADA   (Canada)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h CMAJ   (Canada)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^j MONTREAL CHILDREN S HOSPITAL   (Canada)

^k CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE;

ARTICLE; CANADA; CATECHOLAMINE URINE LEVEL; CHILD; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MORTALITY; NEUROBLASTOMA; PRIORITY JOURNAL; UNITED STATES;

CANADA; CASE-CONTROL STUDIES; CATECHOLAMINES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HOMOVANILLIC ACID; HUMANS; INFANT; INFANT, NEWBORN; MALE; MASS SCREENING; NEONATAL SCREENING; NEOPLASM STAGING; NEUROBLASTOMA; QUEBEC; UNITED STATES; VANILMANDELIC ACID;

EID: 0037018509     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa012387     Document Type: Article

References (29)

1. A population-based study of neuroblastoma incidence, survival and mortality in North America
2. Biology and treatment of neuroblastoma
3. Mass screening for neuroblastoma in infants in Japan: Interim report of a mass screening study group
4. Effects of the mass screening of neuroblastoma in Sapporo City
5. Do children benefit from mass screening for neuroblastoma? Consensus statement from the American Cancer Society Workshop on Neuroblastoma Screening
6. Screening for neuroblastoma in infants: More questions than answers
7. Screening for neuroblastoma at 3 weeks of age: Methods and preliminary results from the Quebec Neuroblastoma Screening Project
8. Screening for neuroblastoma in North America: 2-year results from the Quebec Project
9. A population-based study of the usefulness of screening for neuroblastoma
10. Quebec urinary screening program: A service to the population: A new perspective
11. Studies of catecholamine excretion by children with neural tumors
12. Biological aspects of neuroblastomas identified by mass screening in Quebec
13. Incidence of childhood cancer: Experience of a decade in a population-based registry
14. Childhood cancer in the United States: A geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups
15. Incidence and mortality of neuroblastoma in Canada compared with other childhood cancers
16. Statistical methods in cancer research
17. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children
18. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan
19. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: A chromosome and N-myc amplification study
20. Mass screening for neuroblastoma at 6 months of age: Difficult to justify
21. Effects of mass screening on age-specific incidence of neuroblastoma
22. Report of the 1998 Consensus Conference on Neuroblastoma Screening
23. Randomized controlled trials in population -based intervention studies are not always feasible
24. Neuro-blastoma screening in the United States: Results of the Texas Outreach Program for neuroblastoma screening
25. Neuroblastoma screening at one year of age
26. Neuroblastoma represents distinct clinical-biologic entities: A review and perspective from the Quebec Neuroblastoma Screening Project
27. Molecular basis of clinical heterogeneity in neuroblastoma
28. Spontaneous regression of localized neuroblastoma detected by mass screening